No Local Production Plans for Kalbe Farma's Remdesivir, Covifor Medication
Translator
Ricky Mohammad Nugraha
Editor
Laila Afifa
Jumat, 2 Oktober 2020 08:16 WIB
TEMPO.CO, Jakarta -Kalbe Farma president director Vidjongtius on Thursday said that the publicly listed pharmaceutical firm has not planned to produce the antiviral medication Remdesivir, and it’s generic version Covifor, in Indonesia. He said it will continue focusing on the marketing and distribution of the coronavirus medication.
“There have not been any talks yet [about domestic production] because the factory is indeed in Hetero, India. We currently have no plans yet to invest in a factory,” said Vidjongtius on October 1, 2020.
Kalbe Farma’s confirmation differs to the plans by Kimia Farma which has announced that it will produce the Avigan medication in Indonesia.
Vidjongtius explained that Kalbe and Amarox Pharma Global - Hetero’s subsidiary in India - to market the medication using Amarox’s widespread network in Indonesia.
He assured that the marketing of the medication has obtained permits from the BPOM and that it is exclusively aimed at healthcare facilities to help treat COVID-19 patients in critical condition.
